Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
1999-03-05
2004-01-13
Nguyen, Dave T. (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C536S024500, C435S325000
Reexamination Certificate
active
06677152
ABSTRACT:
BACKGROUND OF THE INVENTION
Cancer of the prostate is a major clinical problem with the diagnosis of 244,000 new cases and more than 40,500 deaths of American men predicted by the American Cancer Society in 1995. Currently, the predicted lifetime incidence of prostate cancer is 15% and the estimated lifetime death risk from this disease is approximately 3.4%. It is not possible by present technologies to distinguish between cancers that will become clinically aggressive versus indolent cancers that will remain clinically benign. Current treatment protocols, including hormonal therapy, radiation therapy and surgery have limitations. Hormonal therapy requires a hormone-responsive tumor; when a tumor develops hormone-insensitivity it can progress unchecked. Attempts at cure using radiation therapy and surgery are limited to eradication of the primary tumors. However, tumor can escape surgical or radiotherapeutic ablation, and these approaches cannot be used to successfully cure, and rarely even to limit metastatic disease. In addition, even when successful, these approaches can significantly diminish the patient's quality of life. These findings emphasize the need for improved diagnostic and therapeutic approaches for identifying prostate carcinomas, predicting clinical aggressiveness and effectively treating patients with this cancer.
Identifying the genetic elements mediating prostate cancer development and progression will lead to improved diagnostic tests and may ultimately result in gene-, immunological- and drug-based technologies with therapeutic applications. Transfection of human prostate carcinoma (LNCaP) DNA into a new DNA acceptor cell line, CREF-Trans 6, and injection into nude mice results in tumor formation (Su et al., Anticancer Res. 12:297-304, 1992). Using tumor-derived CREF-Trans 6 cells and differential RNA display, the new putative oncogene, prostate tumor inducing gene-1 (PTI-1), has been identified (Shen et al., PNAS 92: 6788-6782, 1995). PTI-1 encodes a mutated and truncated human elongation factor-1&agr; (EF-1&agr;). Normal EF-1&agr; plays a prominent role in protein translation, a process that is critical in controlling gene expression and regulating cell growth. PTI-1 expression is observed in human prostate cancer cell lines (LNCaP, DU-145 and PC-3) and patient-derived prostate carcinoma tissue samples (14 of 15), but not in normal prostate (6) or BPH (4) tissue. This observation suggests that PTI-1 expression may be related specifically to carcinoma development. In addition, the observation that PTI-1 expression also occurs in a high proportion of carcinoma cell lines of the breast, colon and lung indicates that this genetic alteration may be a common event in carcinogenesis. If the modified EF-1&agr; protein encoded by PTI-1 inhibits the ability of normal EF-1&agr; to proofread mistakes in gene expression that mediate altered protein structure, then PTI-1 may function as a major contributor to the mutator phenotype in specific human cancers. This putative aberrant processing resulting from PTI-1 expression has been termed “translational infidelity”. If this hypothesis is validated experimentally, altered protein translation would represent a new and novel mechanism underlying cancer development and progression.
Targeted inhibition of PTI-1, using genetic and/or drug interventional approaches, might therefore provide the basis for a novel strategy for the therapy of prostate cancer.
SUMMARY OF THE INVENTION
This invention provides a method for reversing cancer phenotype of a cancer cell which comprises introducing a molecule capable of specifically recognizing a Prostate Tumor Inducing Gene into the cell under conditions permitting inhibition of the expression of said gene so as to thereby reverse the cancer phenotype of the cell.
This invention also provides a method for reversing cancer phenotype of a cancer cell in a subject which comprises introducing a molecule capable of specifically recognizing a Prostate Tumor Inducing Gene into the subject's cancer cell under conditions permitting inhibition of the expression of said gene in the subject's cell so as to thereby reverse the cancer phenotype of the cell.
This invention provides a method for reversing cancer phenotype of a cancer cell which comprises introducing a compound capable of specifically recognizing the RNA of a Prostate Tumor Inducing Gene into the cell under conditions permitting inhibition of the expression of said RNA so as to thereby reverse the cancer phenotype of the cell.
This invention also provides a method for reversing cancer phenotype of a cancer cell in a subject which comprises introducing a compound capable of specifically recognizing the RNA of a Prostate Tumor Inducing Gene into the subject's cancer cell under conditions permitting inhibition of the expression of said RNA in the subject's cell so as to thereby reverse the cancer phenotype of the cell.
This invention provides a method for reversing cancer phenotype of a cancer cell which comprises introducing a substance capable of specifically recognizing the gene product of a Prostate Tumor Inducing Gene into the cell under conditions permitting inhibition of the function of said gene product so as to thereby reverse the cancerous phenotype of the cell.
This invention provides a method for reversing cancer phenotype of a cancer cell in a subject which comprises introducing a substance capable of specifically recognizing the gene product of a Prostate Tumor Inducing Gene into the subject's cancer cell under conditions permitting inhibition of the function of said gene product in the subject's cell so as to thereby reverse the cancer phenotype of the cell.
REFERENCES:
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5851764 (1998-12-01), Fisher et al.
patent: 9115580 (1991-10-01), None
patent: 9621671 (1996-07-01), None
Plenat (J. Mol. Med. Today, vol. 2, No. 6:250-257, 1996).*
Stull et al., Pharmaceutical Res., vol. 12, pp. 465-483, 1995).*
Kausch et al. (The J. of Urology, vol. 168, pp. 239-247, 2002).*
Mastrangelo et al. (Seminars in Oncology, 1996, vol. 23, 1:4-21).*
Coghlan (New Scientist, vol. 148, 13-14, 1995).*
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics- Ninth Edition McGraw-Hill: 77-101, 1996.*
Orkin et al., “Report and recommendations of the panel to assess the NIH investment in research on gene therapy.” pp. 1-20, Dec. 1995.*
Crystal R. “Transfer of genes to humans: Early lessons and obstacles to success.” Science, vol. 270: 404-410, 1995.*
Verma et al., “Gene therapy- promises, problems and prospects.” Nature, vol. 389: 239-242, Sep. 1997.*
Deonarain M., “Ligand-targeted receptor-mediated vectors for gene delivery.” Exp. Opin. Ther. Patents, vol. 8 (1): 53-69, 1998.*
Miller et al., “Targeted vectors for gene therapy.”-FASEB, vol. 9:190-199, Feb. 1995.*
Ledley, Pharmaceutical Res., vol. 13: 1595-1614, 1996.*
Branch A D., TIBS 23: 45-50, Feb. 1998.*
Shen et al., Proc. Natl. Acad. Sci. USA, vol. 92 (15): 6778-6782, 1995.*
Merrick, W.C., (1992) “Mechanism and Regulation of Eukaryotic Protein Synthesis”Microbiol Rev., 56:291-315 (Exhibit 1).
Hwang, Y.W., et al., (1989) “Mutagenesis of Bacterial Elongation Factor Tu at Lysine 136”J.Biol.Chem., 264:8304-8306 (Exhibit 2).
Tapio, S., and Kurland, C.G., (1986) “Mutant EF-Tu increases missense error in vitro”Mol. Gen. Genet., 205:186-188 (Exhibit 3).
Hughes, D. et al., (1987) “Mutants of elongation factor Tu promote ribosomal frameshifting and nonsense readthrough”Embo. J., 6:4235-4239 (Exhibit 4).
Sandbaken, M.G., and Culberston, M.R., (1988) “Mutations in Elongation Factor EF-1&agr; Affect the Frequency of meshifting and Amino Acid Misincorporation in Saccharomyces cerevisiae”Genetics, 120:923-934 (Exhibit 5); and.
Song, J.M. et al., (1989) “Elongation Factor EF-1&agr; Gene Dosage Alters Translational Fidelity in Saccharomyces cerevisiae”Mol. Cell. Biol., 9:4571-4575 (Exhibit 6).
De Benedetti et al. (1994). CHO Cells Transformed by the Translation Factor elF-4E Display Incr
Baker & Botts L.L.P.
Nguyen Dave T.
The Trustees of Columbia University in the City of New York
LandOfFree
Reversal of cancer phenotype by inhibiting expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversal of cancer phenotype by inhibiting expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversal of cancer phenotype by inhibiting expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3201877